• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tirzepatide and glucagon-like peptide-1 receptor agonists: safety always comes first!

作者信息

Patoulias Dimitrios, Caprio Massimiliano, Stoian Anca Pantea, Rizzo Manfredi

机构信息

Outpatient Department of Cardiometabolic Medicine, Second Department of Cardiology, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Second Department of Internal Medicine, European Interbalkan Medical Center, Thessaloniki, Greece.

出版信息

Expert Opin Drug Saf. 2023 Jul-Dec;22(9):763-765. doi: 10.1080/14740338.2023.2247984. Epub 2023 Aug 18.

DOI:10.1080/14740338.2023.2247984
PMID:37584280
Abstract
摘要

相似文献

1
Tirzepatide and glucagon-like peptide-1 receptor agonists: safety always comes first!替尔泊肽与胰高血糖素样肽-1受体激动剂：安全始终是首要的！
Expert Opin Drug Saf. 2023 Jul-Dec;22(9):763-765. doi: 10.1080/14740338.2023.2247984. Epub 2023 Aug 18.
2
Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.替尔泊肽：一种葡萄糖依赖性胰岛素促泌多肽（GIP）和胰高血糖素样肽-1（GLP-1）双重激动剂，正在开发用于治疗 2 型糖尿病。
Expert Rev Endocrinol Metab. 2020 Nov;15(6):379-394. doi: 10.1080/17446651.2020.1830759. Epub 2020 Oct 8.
3
Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.高剂量胰高血糖素样肽-1、胰高血糖素样肽-1/葡萄糖依赖性胰岛素释放肽和胰高血糖素样肽-1/胰高血糖素受体激动剂在 2 型糖尿病中的疗效和安全性。
Diabetes Obes Metab. 2022 May;24(5):788-805. doi: 10.1111/dom.14640. Epub 2022 Jan 21.
4
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.双重葡萄糖依赖性胰岛素促胰岛素多肽（GIP）和胰高血糖素样肽-1（GLP-1）受体激动剂替西帕肽：一种新的代谢治疗前景。
Cardiovasc Diabetol. 2021 Nov 24;20(1):225. doi: 10.1186/s12933-021-01412-5.
5
The new dual gastric inhibitory peptide/glucagon-like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?新型双重胃抑制肽/胰高血糖素样肽-1激动剂替尔泊肽治疗2型糖尿病：前景光明吗？
Diabetes Metab Res Rev. 2021 Nov;37(8):e3503. doi: 10.1002/dmrr.3503. Epub 2021 Oct 15.
6
Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.比较基于肠促胰岛素的降糖药物与基础胰岛素的头对头临床试验的荟萃分析：最新进展，包括最近开发的胰高血糖素样肽-1（GLP-1）受体激动剂和葡萄糖依赖性促胰岛素多肽/GLP-1受体共激动剂替尔泊肽。
Diabetes Obes Metab. 2023 May;25(5):1361-1371. doi: 10.1111/dom.14988. Epub 2023 Feb 8.
7
A comment on tirzepatide versus glucagon-like peptide-1 receptor agonists and heart rate with regard to 'Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis'.关于“双重葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1受体激动剂替尔泊肽对2型糖尿病患者心率的影响：一项系统评价及成对和网状荟萃分析”中替尔泊肽与胰高血糖素样肽-1受体激动剂及心率的评论
Diabetes Obes Metab. 2024 Mar;26(3):1138-1141. doi: 10.1111/dom.15381. Epub 2023 Nov 28.
8
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.使用双重 GIP/GLP-1 受体激动剂替西帕肽治疗 2 型糖尿病：系统评价和荟萃分析。
Diabetologia. 2022 Aug;65(8):1251-1261. doi: 10.1007/s00125-022-05715-4. Epub 2022 May 17.
9
The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.新型双重葡萄糖依赖性胰岛素促分泌素和胰高血糖素样肽-1（GLP-1）受体激动剂替西帕肽可暂时延缓胃排空，类似于选择性长效 GLP-1 受体激动剂。
Diabetes Obes Metab. 2020 Oct;22(10):1886-1891. doi: 10.1111/dom.14110. Epub 2020 Jul 13.
10
Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy.替尔泊肽在2型糖尿病管理中的概况：设计、研发及治疗地位
Expert Opin Pharmacother. 2023 Mar;24(4):407-418. doi: 10.1080/14656566.2023.2181074. Epub 2023 Feb 26.

引用本文的文献

1
A real-world disproportionality analysis of tirzepatide-related adverse events based on the FDA Adverse Event Reporting System (FAERS) database.基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库的替尔泊肽相关不良事件的真实世界不成比例性分析。
Endocr J. 2025 Mar 3;72(3):273-283. doi: 10.1507/endocrj.EJ24-0286. Epub 2024 Nov 27.
2
Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group.心脏代谢连续体的现代管理：从超重/肥胖到糖尿病前期/2型糖尿病。东欧和南欧糖尿病与肥胖专家组的建议。
Diabetes Ther. 2024 Sep;15(9):1865-1892. doi: 10.1007/s13300-024-01615-5. Epub 2024 Jul 11.